A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague (Q41461629)

1 October 2017

A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague (English)

1 reference

1 October 2017

1 reference

9

1 reference

1 October 2017

8

Jon Goguen

1 reference

1 October 2017

Shixia Wang

1

1 reference

1 October 2017

Destin Heilman

2

1 reference

1 October 2017

Fangjun Liu

3

1 reference

1 October 2017

Theodore Giehl

4

1 reference

1 October 2017

Swati Joshi

5

1 reference

1 October 2017

Xiaoyun Huang

6

1 reference

1 October 2017

Te-hui Chou

7

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

1 October 2017

1 reference

1 October 2017

22

1 reference

1 October 2017

25-26

1 reference

1 October 2017

3348-3357

1 reference

A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Yersinia pestis--etiologic agent of plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Effects of Fraction I from Yersinia pestis on Phagocytosis In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Differential effects of deletions in lcrV on secretion of V antigen, regulation of the low-Ca2+ response, and virulence of Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

A surface protease and the invasive character of plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Antigen engineering in DNA immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Probing molecular interactions in intact antibody: antigen complexes, an electrospray time-of-flight mass spectrometry approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

The HIV-1 Env Protein Signal Sequence Retards Its Cleavage and Down-regulates the Glycoprotein Folding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Intranasal vaccination against plague, tetanus and diphtheria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

7 January 2021

inferred from DOI database lookup

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

7 January 2021

inferred from DOI database lookup

Structural organization of virulence-associated plasmids of Yersinia pestis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.036

7 January 2021

inferred from DOI database lookup

Delivery of DNA to skin by particle bombardment

1 reference

12 December 2020

LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism

1 reference

12 December 2020

A new improved sub-unit vaccine for plague: the basis of protection

1 reference

12 December 2020

Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization.

1 reference

12 December 2020

Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus

1 reference

12 December 2020

A single dose sub-unit vaccine protects against pneumonic plague

1 reference

12 December 2020

Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization

1 reference

12 December 2020

Antigen F1 from Yersinia pestis forms aqueous channels in lipid bilayer membranes

1 reference

12 December 2020

Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague

1 reference

12 December 2020

Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge

1 reference

12 December 2020

10.1016/J.VACCINE.2004.02.036

Identifiers

DOI

1 reference

1 October 2017

0 references

1 reference